CSF2 and neoplasm: The vaccination protocol combines the subcutaneous implantation of MVX-ONCO-1, an ECT device containing a human cell line secreting GM-CSF, with the injection of autologous irradiated cells isolated from the patient’s tumor (Figure 4).